Curated News
By: NewsRamp Editorial Staff
June 26, 2026
Burcon Nutrascience Ramps Production, Revenue Up 50% Sequentially
TLDR
- Burcon's growing customer volume and 60% output increase give it an edge in plant-based protein market.
- Burcon completed commissioning and launched production of pea, canola, and fava proteins, with revenue growing sequentially.
- Burcon's plant-based proteins support sustainable food sources, helping create a better tomorrow through eco-friendly nutrition.
- Burcon set a new production record with daily output 60% above earlier levels, showing rapid operational progress.
Impact - Why it Matters
This news matters because Burcon Nutrascience is emerging as a key player in the rapidly growing plant protein market, which is driven by increasing consumer demand for sustainable and alternative protein sources. The company's successful transition to commercial production and strong sequential revenue growth indicate that it is well-positioned to capture market share. For investors, the ramp-up in production and broadening customer base could lead to improved profitability as fixed costs are absorbed. For the food industry, Burcon's diverse protein portfolio—including pea, canola, and fava proteins—offers innovative ingredients that can be used in a wide range of products, from plant-based meats to dairy alternatives. As the global protein shift accelerates, Burcon's progress signals that it can deliver scalable, high-quality proteins to meet growing demand.
Summary
DALLAS, TX -- June 26th, 2026 -- Burcon Nutrascience Corporation (TSX: BU) is gaining momentum as it transitions from commissioning to early utilization, according to a research update from Stonegate Capital Partners. The company has successfully launched commercial production across its plant protein portfolio, including Peazazz pea protein, Puratein C canola protein, and FavaPro fava protein. Revenue in the fourth quarter of fiscal 2026 reached $0.83 million, up from $0.74 million in the prior quarter, and management indicated that current-quarter sales are tracking toward approximately 50% sequential growth based on April and May activity. Burcon also set a new production record, with daily output roughly 60% above January-March levels. As volume builds, the margin opportunity should come from better fixed-cost absorption, steadier production cadence, and start-up costs moving out of the run-rate cost structure, rather than pricing alone.
Burcon's customer traction is broadening, with over 30 purchasing customers and more than 200 active projects across pea, canola, and fava applications. The company's funding supports the Galesburg scale-up, with $6.9 million completed, $3.0 million undrawn, and management targeting $10 million of CY26 sales. Stonegate Capital Partners, a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services, has updated its coverage on Burcon to reflect these positive developments. The full announcement, including downloadable images and bios, can be accessed by clicking here.
Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies. The update highlights Burcon's progress in scaling production and expanding its customer base, positioning the company for significant revenue growth in the coming fiscal year.
Source Statement
This curated news summary relied on content disributed by Reportable. Read the original source here, Burcon Nutrascience Ramps Production, Revenue Up 50% Sequentially
